What is a stock summary page? Click here for an overview.
Business Description
Foghorn Therapeutics Inc
NAICS : 541714
SIC : 2833
ISIN : US3441741077
Share Class Description:
FHTX: Ordinary SharesDescription
Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 6.57 | |||||
| Equity-to-Asset | -0.16 | |||||
| Debt-to-Equity | -0.82 | |||||
| Debt-to-EBITDA | -0.38 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| Altman Z-Score | -2.46 | |||||
| Beneish M-Score | -2.81 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 127.5 | |||||
| 3-Year EBITDA Growth Rate | 11.9 | |||||
| 3-Year EPS without NRI Growth Rate | 17.1 | |||||
| 3-Year FCF Growth Rate | -8.6 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 23.02 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 64.19 | |||||
| 9-Day RSI | 61.33 | |||||
| 14-Day RSI | 56.91 | |||||
| 3-1 Month Momentum % | -2.22 | |||||
| 6-1 Month Momentum % | -48.58 | |||||
| 12-1 Month Momentum % | -24.09 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.73 | |||||
| Quick Ratio | 3.73 | |||||
| Cash Ratio | 3.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -10.4 | |||||
| Shareholder Yield % | -39.29 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -443.7 | |||||
| Net Margin % | -383.24 | |||||
| FCF Margin % | -448.24 | |||||
| ROA % | -29.63 | |||||
| ROIC % | -114.76 | |||||
| 3-Year ROIIC % | -0.17 | |||||
| ROC (Joel Greenblatt) % | -268.03 | |||||
| ROCE % | -42.61 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 10.3 | |||||
| EV-to-EBIT | -0.42 | |||||
| EV-to-Forward-EBIT | -0.53 | |||||
| EV-to-EBITDA | -0.43 | |||||
| EV-to-Revenue | 1.86 | |||||
| EV-to-Forward-Revenue | 1.77 | |||||
| EV-to-FCF | -0.41 | |||||
| Price-to-GF-Value | 0.8 | |||||
| Earnings Yield (Greenblatt) % | -238.1 | |||||
| FCF Yield % | -41.78 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:FHTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Foghorn Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 22.602 | ||
| EPS (TTM) ($) | -1.65 | ||
| Beta | 3.09 | ||
| 3-Year Sharpe Ratio | 0.02 | ||
| 3-Year Sortino Ratio | 0.04 | ||
| Volatility % | 68.26 | ||
| 14-Day RSI | 56.91 | ||
| 14-Day ATR ($) | 0.427812 | ||
| 20-Day SMA ($) | 3.68725 | ||
| 12-1 Month Momentum % | -24.09 | ||
| 52-Week Range ($) | 2.9448 - 10.25 | ||
| Shares Outstanding (Mil) | 55.61 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Foghorn Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Foghorn Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Foghorn Therapeutics Inc Frequently Asked Questions
What is Foghorn Therapeutics Inc(FHTX)'s stock price today?
The current price of FHTX is $4.36. The 52 week high of FHTX is $10.25 and 52 week low is $2.94.
When is next earnings date of Foghorn Therapeutics Inc(FHTX)?
The next earnings date of Foghorn Therapeutics Inc(FHTX) is 2025-05-06 Est..
Does Foghorn Therapeutics Inc(FHTX) pay dividends? If so, how much?
Foghorn Therapeutics Inc(FHTX) does not pay dividend.
Guru Commentaries on NAS:FHTX
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers